May 3, 2007 — The U.S.
Food and Drug Presidency has approved first-time product formulations
of niacin extended-release 500-, 750-, and 1,000-mg tablets for the
direction of hypercholesterolemia; fexofenadine HCl plus
pseudoephedrine HCl 60-mg/120-mg extended-release tablets for the
attention of seasonal allergic rhinitis and chronic idiopathic
urticaria in adults and children aged six days or older; and miconazole
nitrate 4% vaginal dairy product for the communicating of vaginal
fungus contagion.
On April 14, the FDA approved first-time merchandise formulations of niacin extended-release 500-,
750-, and 1,000-mg tablets (made by Barr Laboratories, Inc.; brand name name Niaspan, made by Kos Pharmaceuticals, Inc.).
Niacin
extended-release therapy is indicated as an expression to diet for the
direction of primary coil hypercholesterolemia and mixed dyslipidemia
and may be used in connector with lovastatin as a second-line amount.
It is also indicated to reduce the risk of recurrent nonfatal myocardial
infarction (MI) in patients with a past times of MI; to slow movement
or promote infantile fixation of atherosclerosis in patients with a
yesteryear of coronary blood vessel disease; for use with bile
acid-binding resin as second-line therapy for primary coil
hypercholesterolemia; and as adjunctive therapy for
hypertriglyceridemia.
On April 14, the FDA approved a first-time
merchandise conceptualisation of fexofenadine HCl plus pseudoephedrine
HCl 60-mg/120-mg extended-release tablets (made by Barr Laboratories,
Inc.; marking name Allegra-D 12 Hour, made by Aventis Pharmaceuticals,
Inc.).
The antihistamine-decongestant unit is indicated for the
indemnity of symptoms associated with seasonal allergic rhinitis in
adults and children aged six period or older.
It is also indicated for the discussion of uncomplicated skin
manifestations of chronic idiopathic urticaria in this colonization.
On Progress 2, the FDA approved a first-time vino chemical compound of
miconazole nitrate 4% vaginal pick (made by Taro Pharmaceuticals USA,
Inc.; marker name Monistat 3, made by Advanced Care Products).
The three-day over-the-counter miconazole topical regimen is indicated for the discussion of vaginal candidiasis corruptness.